| ADAR-mediated RNA editing predicts progression and prognosis of gastric cancer THM Chan, A Qamra, KT Tan, J Guo, H Yang, L Qi, JS Lin, VHE Ng, ... Gastroenterology 151 (4), 637-650. e10, 2016 | 162 | 2016 |
| VHL Deficiency Drives Enhancer Activation of Oncogenes in Clear Cell Renal Cell Carcinoma X Yao, J Tan, KJ Lim, J Koh, WF Ooi, Z Li, D Huang, M Xing, YS Chan, ... Cancer discovery 7 (11), 1284-1305, 2017 | 139 | 2017 |
| Epigenomic profiling of primary gastric adenocarcinoma reveals super-enhancer heterogeneity WF Ooi, M Xing, C Xu, X Yao, MK Ramlee, MC Lim, F Cao, K Lim, D Babu, ... Nature communications 7 (1), 12983, 2016 | 138 | 2016 |
| Nanoscale chromatin profiling of gastric adenocarcinoma reveals cancer-associated cryptic promoters and somatically acquired regulatory elements M Muratani, N Deng, WF Ooi, SJ Lin, M Xing, C Xu, A Qamra, ST Tay, ... Nature communications 5 (1), 4361, 2014 | 82 | 2014 |
| Epigenomic promoter alterations amplify gene isoform and immunogenic diversity in gastric adenocarcinoma A Qamra, M Xing, N Padmanabhan, JJT Kwok, S Zhang, C Xu, YS Leong, ... Cancer discovery 7 (6), 630-651, 2017 | 53 | 2017 |
| Epigenomic promoter alterations predict for benefit from immune checkpoint inhibition in metastatic gastric cancer R Sundar, KK Huang, A Qamra, KM Kim, ST Kim, WK Kang, ALK Tan, ... Annals of Oncology 30 (3), 424-430, 2019 | 51 | 2019 |
| HoxC5 and miR-615-3p target newly evolved genomic regions to repress hTERT and inhibit tumorigenesis TD Yan, WF Ooi, A Qamra, A Cheung, DL Ma, GM Sundaram, C Xu, ... Nature communications 9 (1), 100, 2018 | 49 | 2018 |
| HNF4α pathway mapping identifies wild-type IDH1 as a targetable metabolic node in gastric cancer C Xu, WF Ooi, A Qamra, J Tan, BYJ Chua, SWT Ho, K Das, ZFA Isa, Z Li, ... Gut 69 (2), 231-242, 2020 | 40 | 2020 |
| Prognostic and predictive biomarkers in patients with coronavirus disease 2019 treated with tocilizumab in a randomized controlled trial J Tom, M Bao, L Tsai, A Qamra, D Summers, M Carrasco-Triguero, ... Critical Care Medicine 50 (3), 398-409, 2022 | 32 | 2022 |
| Epigenetic promoter alterations in GI tumour immune-editing and resistance to immune checkpoint inhibition R Sundar, KK Huang, V Kumar, K Ramnarayanan, D Demircioglu, Z Her, ... Gut 71 (7), 1277-1288, 2022 | 29 | 2022 |
| Transcriptional analysis of immune genes in Epstein–Barr virus-associated gastric cancer and association with clinical outcomes R Sundar, A Qamra, ALK Tan, S Zhang, CCY Ng, BT Teh, J Lee, KM Kim, ... Gastric Cancer 21, 1064-1070, 2018 | 29 | 2018 |
| Genomic and epigenomic EBF1 alterations modulate TERT expression in gastric cancer M Xing, WF Ooi, J Tan, A Qamra, PH Lee, Z Li, C Xu, N Padmanabhan, ... The Journal of clinical investigation 130 (6), 3005-3020, 2020 | 18 | 2020 |
| CRISPRi enables isoform-specific loss-of-function screens and identification of gastric cancer-specific isoform dependencies R Davies, L Liu, S Taotao, N Tuano, R Chaturvedi, KK Huang, C Itman, ... Genome biology 22, 1-19, 2021 | 17 | 2021 |
| Epigenomic promoter alterations amplify gene isoform and immunogenic diversity in gastric adenocarcinoma. Cancer Discov. 2017; 7: 630–651. doi: 10.1158/2159-8290 A Qamra, M Xing, N Padmanabhan, JJT Kwok, S Zhang, C Xu, YS Leong, ... CD-16-1022.[Abstract][CrossRef][Google Scholar], 0 | 15 | |
| Transposable elements are co-opted as oncogenic regulatory elements by lineage-specific transcription factors in prostate cancer G Grillo, T Keshavarzian, S Linder, C Arlidge, L Mout, A Nand, M Teng, ... Cancer discovery 13 (11), 2470-2487, 2023 | 13 | 2023 |
| Telomere dysfunction cooperates with epigenetic alterations to impair murine embryonic stem cell fate commitment M Criqui, A Qamra, TW Chu, M Sharma, J Tsao, DA Henry, ... Elife 9, e47333, 2020 | 13 | 2020 |
| VHL deficiency drives enhancer activation of oncogenes in clear cell renal cell carcinoma. Cancer Discov. 2017; 7: 1284–1305. doi: 10.1158/2159-8290 X Yao, J Tan, KJ Lim, J Koh, WF Ooi, Z Li, D Huang, M Xing, YS Chan, ... CD-17-0375.[Abstract][CrossRef][Google Scholar], 0 | 13 | |
| Abstract PD10-05: Activity of atezolizumab (atezo) plus paclitaxel (pac) in metastatic triple-negative breast cancer (mTNBC) according to Burstein molecular subtype: Analysis … F André, R Deurloo, A Qamra, D Cameron, J Gligorov, A Schneeweiss, ... Cancer Research 82 (4_Supplement), PD10-05-PD10-05, 2022 | 8 | 2022 |
| Chronic hypoxia favours adoption to a castration-resistant cell state in prostate cancer S Cameron, G Deblois, JR Hawley, A Qamra, S Zhou, SAM Tonekaboni, ... Oncogene 42 (21), 1693-1703, 2023 | 7 | 2023 |
| VHL deficiency drives enhancer activation of oncogenes in clear cell renal cell carcinoma. Cancer Discov. 2017; 7 (11): 1284-1305. doi: 10.1158/2159-8290 X Yao, J Tan, KJ Lim, J Koh, WF Ooi, Z Li CD-17-0375, 0 | 6 | |
Patrick TanDuke-NUS Medical School在 duke-nus.edu.sg 的电子邮件经过验证
